Symbols

IRWD

Ironwood Pharmaceuticals·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 6

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Low Cash Short-term Debt Ratio

Price Hits New Low

Price Hits 52-week Low

Three Black Crows

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IRWD

Ironwood Pharmaceuticals, Inc.

A biopharmaceutical company that develops and commercializes gastrointestinal and inflammatory diseases treatments in the US

Industry

Biological Technology

Established Date

01/05/1998

Listing Date

02/03/2010

Exchange

NASDAQ Stock Exchange

Full-time Employees

253

Fiscal Year Ends

12-31

Website

www.ironwoodpharma.com

Security Type

Common stock

Office address

100 Summer Street, Suite 2300 , Boston, Massachusetts, 02110

Business

Introduction

Ironwood Pharmaceuticals, Inc., was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, a S&P SmallCap 600 company, is a leading gastrointestinal (GI) healthcare company with a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They are pioneers in the development of LINZESS (linaclotide), the market leader in branded prescriptions in the United States, for the treatment of adult irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC) with constipation.

Company Financials

EPS

IRWD has released its 2025 Q3 earnings. EPS was reported at 0.24, versus the expected 0.12, beating expectations. The chart below visualizes how IRWD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IRWD has released its 2025 Q3 earnings report, with revenue of 122.06M, reflecting a YoY change of 33.26%, and net profit of 40.08M, showing a YoY change of 999.29%. The Sankey diagram below clearly presents IRWD's revenue sources and cost distribution.